Physician profile
Demetrio Aguila
NPI 1376503391
$49,934.57
in general payments reported to CMS, 2019-2025
23 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,058 · 2020: $1,719 · 2021: $35K · 2022: $9,617 · 2023: $959 · 2024: $560 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144 · Consulting Fee: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.98 |
| Consulting Fee | $612.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $40,596.33 | 2020-2024 | Sx-One Microknife |
| Smith+Nephew, INC. | $5,653.57 | 2019-2023 | Tula |
| Stryker Corporation | $1,895.98 | 2019-2021 | |
| Kerecis Limited | $308.86 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Musculoskeletal Transplant Foundation INC. | $254.48 | 2020-2022 | |
| Genzyme Corporation | $194.09 | 2019-2022 | |
| Checkpoint Surgical, INC | $189.46 | 2019-2024 | Checkpoint Stimulators |
| Mimedx Group, INC. | $122.99 | 2024-2025 | |
| Alk-Abello, INC | $109.80 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $101.19 | 2025 | |
| Conetic Solutions, INC. | $82.11 | 2023 | |
| Acclarent, INC | $80.99 | 2019-2021 | |
| Axogen | $70.11 | 2019 | |
| Baudax Bio INC. | $54.89 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $50.64 | 2021-2025 | Iovera |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $49.54 | 2024 | Ovitex 2s |
| Misonix INC | $23.88 | 2020 | |
| Spr Therapeutics, INC | $20.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.70 | 2020 | |
| Redhill Biopharma INC. | $15.54 | 2020 | |
| Medtronic, INC. | $14.20 | 2021 | |
| Heron Therapeutics, INC. | $14.10 | 2023 | Zynrelef |
| Integra Lifesciences Corporation | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demetrio Aguila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.